Skip to main content
Considering a New Paradigm for Alzheimer’s Disease Research
  • Gillian R. Langley
Document Type
Publication Date

Using Alzheimer’s disease as a case study, this review argues that it might be time to consider a new paradigm in medical research and drug discovery. The existing framework is overly dependent on often unvalidated animal models, particularly transgenic mice. Translational success remains elusive and costly late-stage drug failure is common. The conventional paradigm tends to overlook species differences and assumes that animal-based findings are generally applicable to humans. Could pathways-based research using advanced human-specific models probed with new tools, including those of systems biology, take centre stage? The current transition in chemical toxicology to a 21st-century paradigm could be a model for health research, with probable medical and economic benefits.


In compliance with the publisher’s copyright and archiving policies, this is a post-print version of the document. Post-print materials contain the same content as their final edited versions, but are not formatted according to the layout of the published book or journal.

Citation Information
Langley, G. R. (2014). Considering a new paradigm for Alzheimer's disease research. Drug discovery today, 19(8), 1114-1124.